Immunoglobulin light chain repertoire in chronic lymphocytic leukemia

Vλ genes in chronic lymphocytic leukaemia: highly skewed V gene segment usage with similar CDR3 sequences

“…However, we also found several V l gene segments (IGL1-41n01, IGL1-47n01, IGL2-14n03 and IGL5-45n03) that had not previously been reported in CLL. There is also over-representation of IGL10-54n01 (6% in this study and 1% in Stamatopoulos et al 6 ) and underrepresentation of IGL2-8n01 (3 and 14% in Stamatopoulos et al 6 ). J2n01 and J3n02 were the predominant J l gene segments used in those cases where an assignment could be made.…”

“…4 Mutational analyses of N-RAS, K-RAS, NPM1, FLT3/ITD, FLT3/TKD, CEBPA, KIT, AML1 and MLL/PTD were performed as previously described. 5,6 The correlation of genetic mutations with clinical and laboratory characteristics is summarized in Supplementary Table 1. Among the 272 AML patients recruited, 165 were males and 107 were females with a median age of 52.5 years (range, 19-90).…”

“…There is much less work on the light-chain V gene usage in CLL but there is a biased usage of both k and l light chains. 6 We have sequenced rearranged V L genes from l expressing cases of CLL. In distinction to the previous work on V l gene usage based on southern European 6 or North American populations, our cases are drawn from northern Europe.…”

“…Analysis of CDR3 regions in CLL has demonstrated that unrelated cases can share structural features 8 and has allowed grouping into subsets, some of which showed homology for only light chains . 6 We undertook an analysis of CDR3 regions in our cases ( Figure 1b). As others have reported, there is a striking similarity between IGL3-21 CDR3 regions in both length (12 amino acids) and sequence.…”

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia

“…[1][2][3][4][5][6][7][8] IGHV mutational status is thus being considered one of the most important prognostic factors to stratify patients in clinical trials. 9 For this reason, recommendations on how to perform and interpret IGHV mutational analysis in CLL are strongly needed to set standards that may allow comparisons between different patient series, thus avoiding discrepancies.…”